Outlook Therapeutics (OTLK) Operating Expenses (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Operating Expenses data on file, last reported at -$9.6 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at -$9.6 million, down 128.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.8 million (up 19.43% YoY), and the FY2025 annual result was -$3.1 million, down 184.27% from the prior year.
• Operating Expenses fell to -$9.6 million in Q1 2026 per OTLK's latest filing, from $12.2 million in the prior quarter.
• Over five years, Operating Expenses peaked at $34.0 million in Q1 2025 and troughed at -$45.2 million in Q3 2024.
• A 5-year average of $11.7 million and a median of $16.3 million in 2025 frame the typical range for Operating Expenses.
• On a YoY basis, Operating Expenses climbed as much as 176.98% in 2024 and fell as far as 462.51% in 2024.
• A 5-year view of Operating Expenses shows it stood at $15.7 million in 2022, then tumbled by 34.2% to $10.3 million in 2023, then soared by 109.31% to $21.6 million in 2024, then slumped by 43.32% to $12.2 million in 2025, then plunged by 178.18% to -$9.6 million in 2026.
• Business Quant data shows OTLK's Operating Expenses at -$9.6 million in Q1 2026, $12.2 million in Q4 2025, and $16.3 million in Q3 2025.